Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study ; volume:21 ; number:1 ; day:29 ; month:5 ; year:2021 ; pages:1-12 ; date:12.2021
BMC cancer ; 21, Heft 1 (29.5.2021), 1-12, 12.2021
- Urheber
-
Dalle, Stéphane
Mortier, Laurent
Corrie, Pippa
Lotem, Michal
Board, Ruth
Arance, Ana María
Meiß, Frank
Terheyden, Patrick
Gutzmer, Ralf
Buysse, Brian
Oh, Kelly
Brokaw, Jane
Le, T. Kim
Mathias, Susan D.
Scotto, Julie
Lord-Bessen, Jennifer
Moshyk, Andriy
Kotapati, Srividya
Middleton, Mark R.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-08032-y
- URN
-
urn:nbn:de:101:1-2021092507421087665434
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dalle, Stéphane
- Mortier, Laurent
- Corrie, Pippa
- Lotem, Michal
- Board, Ruth
- Arance, Ana María
- Meiß, Frank
- Terheyden, Patrick
- Gutzmer, Ralf
- Buysse, Brian
- Oh, Kelly
- Brokaw, Jane
- Le, T. Kim
- Mathias, Susan D.
- Scotto, Julie
- Lord-Bessen, Jennifer
- Moshyk, Andriy
- Kotapati, Srividya
- Middleton, Mark R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Untersuchungen zum Einfluß des arteriellen Leberblutflusses und von Sauerstoff auf die Leberfunktion bei Patienten mit Zirrhose
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – an evaluation of the multicenter prospective skin cancer registry ADOREG
Real world outcomes using PD‐1 antibodies and BRAF+ MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
Ipilimumab in patients with melanoma and autoimmune disease
Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy
Acute visual loss after ipilimumab treatment for metastatic melanoma
Ipilimumab induced digital vasculitis
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Untersuchungen zum Einfluß des arteriellen Leberblutflusses und von Sauerstoff auf die Leberfunktion bei Patienten mit Zirrhose
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – an evaluation of the multicenter prospective skin cancer registry ADOREG
Real world outcomes using PD‐1 antibodies and BRAF+ MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
Ipilimumab in patients with melanoma and autoimmune disease
Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy
Acute visual loss after ipilimumab treatment for metastatic melanoma
Ipilimumab induced digital vasculitis
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Untersuchungen zum Einfluß des arteriellen Leberblutflusses und von Sauerstoff auf die Leberfunktion bei Patienten mit Zirrhose
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – an evaluation of the multicenter prospective skin cancer registry ADOREG
Real world outcomes using PD‐1 antibodies and BRAF+ MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
Ipilimumab in patients with melanoma and autoimmune disease
Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy
Acute visual loss after ipilimumab treatment for metastatic melanoma